IP Library Assignment 067606/0247
Patent Assignment
Reel/Frame 067606/0247

Release of Security Interest

Recorded: 2024-06-03 Pages: 46
Assignor
Assignee
INHIBRX, INC.
11025 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA, CALIFORNIA, 92037
Covered Properties (51)
Wap Domain Fusion Polypeptides and Methods of Use Thereof
Patent: 8,986,688 →
Application: 13/536,987 →
Publication: US 2013/0011399
Wap Domain Fusion Polypeptides and Methods of Use Thereof
Patent: 9,914,765 →
Application: 14/616,351 →
Publication: US 2015/0147324
Serpin Fusion Polypeptides and Methods of Use Thereof
Patent: 8,980,266 →
Application: 13/536,976 →
Publication: US 2013/0011398
Serpin Fusion Polypeptides And Methods Of Purification Thereof
Patent: 9,920,109 →
Application: 13/969,959 →
Publication: US 2013/0330769
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 14/616,363 →
Publication: US 2015/0147325
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 15/875,010 →
Publication: US 2018/0179264
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 17/066,410 →
Publication: US 2021/0024613
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 17/315,511 →
Publication: US 2022/0324944
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 14/524,832 →
Publication: US 2015/0104410
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 16/393,615 →
Publication: US 2020/0115437
Serpin Fusion Polypeptides and Methods of Use Thereof
Application: 16/908,271 →
Publication: US 2021/0002352
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Application: 16/600,298 →
Publication: US 2020/0190193
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Application: 17/524,016 →
Publication: US 2022/0162316
Non-Immunogenic Single Domain Antibodies
Application: 15/003,234 →
Publication: US 2016/0207981
Non-Immunogenic Single Domain Antibodies
Application: 16/685,087 →
Publication: US 2020/0140525
Type Iii Secretion System Targeting Molecules
Application: 15/144,470 →
Publication: US 2016/0318996
Type III Secretion System Targeting Molecules
Application: 16/419,677 →
Publication: US 2019/0345235
Multivalent and Multispecific DR5-Binding Fusion Proteins
Application: 15/213,296 →
Publication: US 2017/0015753
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Treating Neoplasms
Application: 16/387,754 →
Publication: US 2019/0309083
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune Cells
Application: 17/394,900 →
Publication: US 2022/0064318
Multispecific Gitr-Binding Fusion Proteins and Methods of Use Thereof
Application: 15/217,754 →
Publication: US 2017/0022284
Multivalent and Multispecific Glucocorticoid-Induced Tnfr-Related Protein (Gitr)-Binding Single-Domain Antibody Fusion Proteins and Encoding Nucleic Acids
Application: 16/119,950 →
Publication: US 2019/0100594
Multivalent and Multispecific OX40-Binding Fusion Proteins
Application: 16/295,332 →
Publication: US 2019/0263916
Multivalent and Multispecific OX40-Binding Fusion Proteins
Application: 17/398,851 →
Publication: US 2022/0106397
Multivalent and Multispecific 41BB-Binding Fusion Proteins
Application: 15/404,016 →
Publication: US 2017/0198050
PDL1-Binding Proteins
Application: 16/601,825 →
Publication: US 2020/0199243
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Methods of Using the Same
Application: 15/951,137 →
Publication: US 2019/0010242
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Related Methods and Uses
Application: 16/380,963 →
Publication: US 2019/0330366
B7H3 Single Domain Antibodies and Therapeutic Compositions Thereof
Application: 17/283,902 →
Publication: US 2023/0124851
5T4 Single Domain Antibodies and Therapeutic Compositions Thereof
Application: 17/283,830 →
Publication: US 2021/0340273
DLL3 Single Domain Antibodies and Therapeutic Compositions Thereof
Application: 17/283,903 →
Publication: US 2021/0380679
Multispecific Polypeptide Constructs Containing a Constrained CD3 Binding Domain and a Receptor Binding Region and Methods of Using the Same
Application: 16/520,293 →
Publication: US 2020/0048350
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
Application: 17/418,458 →
Publication: US 2022/0089667
OX40-Binding Polypeptides and Uses Thereof
Application: 16/538,216 →
Publication: US 2020/0055946
CD123-Binding Polypeptides and Uses Thereof
Application: 16/864,478 →
Publication: US 2020/0347142
CD33-Binding Polypeptides and Uses Thereof
Application: 16/864,480 →
Publication: US 2020/0347133
CLEC12a Binding Polypeptides and Uses Thereof
Application: 16/864,481 →
Publication: US 2020/0347139
CD123 Targeted Immunotherapies
Application: 17/608,739 →
Publication: US 2022/0315638
CD33 Targeted Immunotherapies
Application: 17/608,743 →
Publication: US 2022/0324942
Cll-1 Targeted Immunotherapies
Application: 17/608,738 →
Publication: US 2022/0323496
CD8-Binding Polypeptides and Uses Thereof
Application: 63/223,786 →
CD8-Binding Polypeptides and Uses Thereof
Application: 63/288,111 →
CD8-Targeted Modified Il-2 Polypeptides and Uses Thereof
Application: 63/223,798 →
CD8-Targeted Modified Il-2 Polypeptides and Uses Thereof
Application: 63/288,113 →
CD33 Targeted Immunotherapies
Application: 63/111,280 →
Formulations of DR5 Binding Polypeptides
Application: 63/151,131 →
NKP46-Binding Polypeptides and Uses Thereof
Application: 63/238,429 →
NKP46-Targeted Modified IL-2 Polypeptides and Uses Thereof
Application: 63/238,431 →
CD47 Antibodies and Methods of Use Thereof
Patent: 9,045,541 →
Application: 13/761,087 →
Publication: US 2013/0224188
CD47 Antibodies and Methods of Use Thereof
Patent: 9,663,575 →
Application: 14/700,105 →
Publication: US 2015/0238604
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
Application: 17/170,854 →
Publication: US 2021/0317205
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 3, 2013
From: TIMMER, JOHN; ECKELMAN, BRENDAN; GUENTHER, GRANT B.; NGUY, PETER L.
To: INHIBRX LLC
Reel/Frame 030530/0405 →
Assignment of Assignor's Interest Aug 30, 2013
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 031115/0609 →
Assignment of Assignor's Interest Oct 24, 2013
From: ECKELMAN, BRENDAN; TIMMER, JOHN; DEVERAUX, QUINN
To: INHIBRX LLC
Reel/Frame 031466/0547 →
Assignment of Assignor's Interest May 11, 2015
From: TIMMER, JOHN; ECKELMAN, BRENDAN; GUENTHER, GRANT B.; NGUY, PETER L.
To: INHIBRX LLC
Reel/Frame 035610/0562 →
Assignment of Assignor's Interest May 11, 2015
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 035610/0709 →
Assignment of Assignor's Interest Apr 14, 2016
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 038281/0055 →
Assignment of Assignor's Interest Oct 20, 2016
From: TIMMER, JOHN C.; JONES, KYLE S.; RAZAI, AMIR S.; HUSSAIN, ABRAHIM
To: INHIBRX LP
Reel/Frame 040073/0748 →
Assignment of Assignor's Interest Aug 4, 2017
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 043195/0189 →
Assignment of Assignor's Interest Nov 15, 2017
From: INHIBRX BIOPHARMA, LLC
To: INHIBRX LP
Reel/Frame 044133/0835 →
Change of Name Nov 28, 2017
From: INHIBRX LLC
To: INHIBRX LP
Reel/Frame 044528/0712 →
Assignment of Assignor's Interest Jan 24, 2018
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 044710/0285 →
Assignment of Assignor's Interest Jan 25, 2018
From: INHIBRX LLC
To: INHIBRX LP
Reel/Frame 045150/0827 →
Assignment of Assignor's Interest Jan 30, 2018
From: INHIBRX BIOPHARMA, LLP
To: INHIBRX LP
Reel/Frame 044762/0734 →
Merger and Change of Name May 22, 2018
From: INHIBRX LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 046215/0084 →
Assignment of Assignor's Interest Apr 30, 2019
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; DEVERAUX, QUINN
To: INHIBRX LP
Reel/Frame 049033/0761 →
Corrective Assignment to Correct the Nature of Conveyance Previously Recorded at Reel: 045150 Frame: 0827. Assignor(S) Hereby Confirms the Change of Name. May 15, 2019
From: INHIBRX, LLC
To: INHIBRX, LP
Reel/Frame 049181/0754 →
Assignment of Assignor's Interest Mar 16, 2020
From: PANDIT, RAJAY A.; TIMMER, JOHN C.; SANABRIA, ANGELICA N.; SULZMAIER, FLORIAN
To: INHIBRX, INC.
Reel/Frame 052121/0250 →
Assignment of Assignor's Interest Jun 11, 2020
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 052912/0929 →
Change of Name Oct 14, 2020
From: INHIBRX, LLC
To: INHIBRX, LP
Reel/Frame 054074/0330 →
Assignment of Assignor's Interest Oct 14, 2020
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 054046/0981 →
Assignment of Assignor's Interest Oct 14, 2020
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 054046/0863 →
Assignment of Assignor's Interest Nov 16, 2021
From: PANDIT, RAJAY A.; TIMMER, JOHN C.; SANABRIA, ANGELICA N.; SULZMAIER, FLORIAN
To: INHIBRX, INC.
Reel/Frame 058121/0619 →
Change of Name Feb 22, 2022
From: INHIBRX LLC
To: INHIBRX, LP
Reel/Frame 059217/0264 →
Assignment of Assignor's Interest Feb 22, 2022
From: ECKELMAN, BRENDAN; TIMMER, JOHN; NGUY, PETER L.; GUENTHER, GRANT B.
To: INHIBRX LLC
Reel/Frame 059065/0307 →
Assignment of Assignor's Interest Feb 22, 2022
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 059065/0321 →